Trials / Terminated
TerminatedNCT05262517
Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for Acute Treatment of Temporomandibular Disorders
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Temporomandibular Disorders (TMD)
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 126 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the efficacy and safety of rimegepant versus placebo in the acute treatment of Temporomandibular Disorders (TMD), which are medical conditions involving the temporomandibular joint (the joint connecting the jawbone to the skull) and surrounding muscles and tissues.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rimegepant | 75 mg ODT |
| DRUG | Placebo | matching placebo |
Timeline
- Start date
- 2022-05-05
- Primary completion
- 2023-05-18
- Completion
- 2023-05-18
- First posted
- 2022-03-02
- Last updated
- 2024-05-16
- Results posted
- 2024-05-16
Locations
32 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05262517. Inclusion in this directory is not an endorsement.